2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
132 hedge funds and large institutions have $436M invested in 2seventy bio in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 22 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 20
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
1% less funds holding
Funds holding: 133 → 132 (-1)
20% less capital invested
Capital invested by funds: $544M → $436M (-$108M)
31% less call options, than puts
Call options by funds: $398K | Put options by funds: $578K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.9M |
| 2 |
BlackRock
New York
|
+$12.7M |
| 3 |
MAP
Madison Avenue Partners
New York
|
+$8.37M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$7.54M |
| 5 |
JP Morgan Chase
New York
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$9.41M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.11M |
| 3 |
AC
Armistice Capital
New York
|
-$5.45M |
| 4 |
6CM
683 Capital Management
New York
|
-$3.84M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.68M |
TSVT Hedge Fund Activity: Q2 2022 in Review
132 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q2 2022, worth a combined $436M — down 20% from $544M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TSVT positions and 22 closed out — a net gain of 3 holders — while 44 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $12.9M. The largest seller was CVI Holdings, cutting an estimated $9.41M.
- 132 institutional investors held 2seventy bio (TSVT) as of Q2 2022, down from 133 in Q1 2022.
- Funds reported $436M of 2seventy bio stock for Q2 2022, down 20% quarter-over-quarter.
- 25 funds opened new 2seventy bio positions in Q2 2022 and 22 closed out, a net change of +3 holders.
- The largest 2seventy bio buyer in Q2 2022 was Vanguard Group, an estimated $12.9M added.
- The largest 2seventy bio seller in Q2 2022 was CVI Holdings, an estimated $9.41M sold.
Based on aggregated 13F filings for Q2 2022.